RxDoctor Payments Data

Nathaniel Robinson, MD

Medical Oncology · Middletown, CTNPI 1235665571

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,720 of the $2,161 with a category attached, or 79.6%. Boehringer Ingelheim accounts for 79.6% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $1,764, 5.9 times the $299 reported in 2021. That places this record below the midpoint for medical oncology clinicians in CT, where the typical reported total is $3,212.

$2,161in general payments, 2019–2025

Across 7 payments — averaging $308.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • Amgen$280
  • Incyte Corporation$99
  • Galvanize Therapeutics, Inc$44
  • Johnson & Johnson$18
$500in research payments, 2019–2025

Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$500

What the payments were for

  • Consulting fees$1,72080%
  • Food & beverage$623%
  • Education$37918%

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,161 in reported general payments places this provider in the 45th percentile of 79 medical oncology providers in Connecticut.

See all medical oncology providers in Connecticut

Medicare billing

Part B allowed, 2024
$305,730
Medicare patients
125
Services billed
28,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →